Gliknik, Inc. and Pfizer have entered into an exclusive worldwide licensing agreement under which Pfizer receives rights to GL-2045, a recombinant stradomer drug candidate designed to replace and improve pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising preclinical results as a potential treatment for a variety of autoimmune diseases, including those in which IVIG is clinically used.   Pfizer will receive exclusive worldwide license to GL-2045 for all therapeutic indica...